OMO-1 is under clinical development by OCTIMET Oncology and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect OMO-1’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 19 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their OMO-1 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
OMO-1 is under development for the treatment of solid malignancies. It is formulated as a capsule and administered orally. The drug candidate is a small molecule which acts by targeting receptor tyrosine kinase.
OCTIMET Oncology overview
OCTIMET Oncology (OCTIMET) is a biotechnology company that offers development of MET kinase inhibitory drug candidates. The company’s product portfolio under preclinical development includes OMO-1, is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase targeting some hereditary types of cancer; OMO-2, a MET-inhibitor is in late non-clinical development. The company develops discovery stage molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies. The company works in partnership with other translational oncology companies for in- and out-licensing opportunities. OCTIMET is headquartered in Beerse, Belgium.
Quick View OMO-1 LOA Data
|Highest Development Stage|